Find Patient Assistance

Answer a few simple questions to find out which patient assistance option might be right for your patient.

  • Is your patient insured?

  • Does your patient have commercial insurance?

    What does this mean?
  • Has your patient been prescribed ACTEMRA Subcutaneous (SC)?

  • Has your patient been prescribed ACTEMRA Intravenous (IV)?

  • Does your patient have prescription drug coverage through a Medicare Advantage or Medicare Part D plan?

  • Has your patient already been referred to the ACTEMRA Co-pay Card Program and is either ineligible or no longer receiving assistance?

  • Has your patient already been referred to an independent co-pay assistance foundation and is either ineligible or no longer receiving assistance?

  • Is the patient using ACTEMRA for an FDA-approved indication?

Your Patient Might Qualify for a Referral to the ACTEMRA Co-pay Card Program

If eligible commercially insured patients need assistance with their out-of-pocket costs, Genentech Rheumatology Access Solutions can refer them to the ACTEMRA Co-pay Card Program.*

 

Learn More

 

*In order to be eligible for the ACTEMRA Co-pay Card Program, the patient must have commercial insurance, must not have Medicare, Medicaid or other government insurance, and must meet other eligibility criteria. They also must agree to the rules set forth in the terms and conditions for the program. Please visit RACopay.com for the full list of terms and conditions.

Your Patient Might Qualify for a Referral to an Independent Co-pay Assistance Foundation

For eligible patients with commercial or public health insurance, Genentech Rheumatology Access Solutions offers referrals to independent co-pay assistance foundations.*

 

Learn More

 

*Genentech does not influence or control the operations or eligibility criteria of any independent co-pay assistance foundation and cannot guarantee co-pay assistance after a referral from Genentech Rheumatology Access Solutions. The foundations to which we refer patients are not exhaustive or indicative of Genentech’s endorsement or financial support. There may be other foundations to support the patient's disease state.

Your Patient Might Qualify for a Referral to the Genentech® Access to Care Foundation (GATCF)

GATCF helps eligible patients who meet specific criteria receive their Genentech medicine free of charge.*

 

Learn More

 

*To be eligible for free Genentech medicine from GATCF, insured patients must have exhausted all other forms of patient assistance (including the ACTEMRA Co-pay Card Program and support from independent co-pay assistance foundations) and meet financial criteria. Uninsured patients must meet different financial criteria.

Please Contact Us

Please call us at (866) 681-3261.

Low-Income Subsidy (LIS) or "Extra Help" From Medicare*

Your patient may qualify for financial assistance with their Medicare prescription drug costs through the Low-Income Subsidy (LIS) program, also known as Extra Help.

 

Learn More or Apply for Extra Help From Medicare

 

*LIS is a Medicare program. Genentech does not influence or control the operations or eligibility of this program. To qualify, patients must meet certain financial criteria. For more information, patients can contact Social Security at (800) 772-1213 or visit SocialSecurity.gov/extrahelp.

Patient Assistance Options

Referrals to the ACTEMRA Co-pay Card Program 

Genentech Rheumatology Access Solutions can refer eligible patients to the ACTEMRA Co-pay Card Program for help with the out-of-pocket costs associated with their Genentech medicine.*

Learn More

Referrals to Independent
Co-pay Assistance Foundations

For eligible patients with commercial or public health insurance, Genentech Rheumatology Access Solutions offers referrals to independent co-pay assistance foundations.†

Learn More

Referrals to the Genentech® Access to Care Foundation (GATCF)

GATCF helps eligible patients who meet specific criteria receive their Genentech medicine free of charge.‡

Learn More

*In order to be eligible for the ACTEMRA Co-pay Card Program, the patient must have commercial insurance, must not have Medicare, Medicaid or other government insurance, and must meet other eligibility criteria. They also must agree to the rules set forth in the terms and conditions for the program. Please visit RACopay.com for the full list of terms and conditions.

†Genentech does not influence or control the operations or eligibility criteria of any independent co-pay assistance foundation and cannot guarantee co-pay assistance after a referral from Genentech Rheumatology Access Solutions. The foundations to which we refer patients are not exhaustive or indicative of Genentech’s endorsement or financial support. There may be other foundations to support the patient's disease state.

‡To be eligible for free Genentech medicine from GATCF, insured patients must have exhausted all other forms of patient assistance (including the ACTEMRA Co-pay Card Program and support from independent co-pay assistance foundations) and meet financial criteria. Uninsured patients must meet different financial criteria.

PAN=Patient Authorization and Notice of Request for Transmission of Health Information to Genentech Access Solutions and Genentech® Access to Care Foundation.

SMN=Statement of Medical Necessity.

Important Safety Information & Indication

Indication

ACTEMRA® (tocilizumab) is indicated for the treatment of:

  • Adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more Disease-Modifying Anti-Rheumatic Drugs (DMARDs)
  • Giant cell arteritis (GCA) in adult patients
  • Active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older
  • Active systemic juvenile idiopathic arthritis in patients 2 years of age and older
  • Chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome in adults and pediatric patients 2 years of age and older

Important Safety Information

RISK OF SERIOUS INFECTIONS:

Patients treated with ACTEMRA are at increased risk for developing serious infections that may lead to hospitalization or death, including tuberculosis (TB), bacterial, invasive fungal, viral, or other opportunistic infections. If a serious infection develops, interrupt ACTEMRA until the infection is controlled.

Reported infections include:

  • Active tuberculosis, which may present with pulmonary or extrapulmonary disease. Patients should be tested for latent tuberculosis before ACTEMRA use and during therapy. Treatment for latent infection should be initiated prior to ACTEMRA use.
  • Invasive fungal infections, including candidiasis, aspergillosis, and pneumocystis. Patients with invasive fungal infections may present with disseminated, rather than localized, disease.
  • Bacterial, viral and other infections due to opportunistic pathogens.

The risks and benefits of treatment with ACTEMRA should be carefully considered prior to initiating therapy in patients with chronic or recurrent infection.

Patients should be closely monitored for the development of signs and symptoms of infection during and after treatment with ACTEMRA, including the possible development of tuberculosis in patients who tested negative for latent tuberculosis infection prior to initiating therapy.

ACTEMRA is contraindicated in patients with known hypersensitivity to ACTEMRA.

Other serious or potentially life-threatening adverse reactions that have been reported in clinical trials with ACTEMRA include gastrointestinal perforations. Use ACTEMRA with caution in patients who may be at risk for GI perforations.

Laboratory monitoring is recommended due to potential consequences of treatment-related laboratory abnormalities in neutrophils, platelets, lipids, and liver function tests.

ACTEMRA is an immunosuppressant, and treatment with immunosuppressants may result in an increased risk of malignancies.

Hypersensitivity reactions, including anaphylaxis and death, have occurred.

  • If anaphylaxis or other hypersensitivity reaction occurs, stop administration of ACTEMRA immediately and discontinue ACTEMRA permanently.

The impact of treatment with ACTEMRA on demyelinating disorders is not known. Monitor patients for signs and symptoms potentially indicative of demyelinating disorders.

Treatment with ACTEMRA is not recommended in patients with active hepatic disease or hepatic impairment.

Avoid use of live vaccines concurrently with ACTEMRA, as clinical safety has not been established.

Most common adverse reactions included upper respiratory tract infections, nasopharyngitis, headache, hypertension, increased ALT, and injection-site reactions (SC only).

You may report side effects to the FDA at (800) FDA-1088 or http://www.fda.gov/medwatch. You may also report side effects to Genentech at (888) 835-2555.

Please see the full Prescribing Information, including BOXED WARNING, for additional Important Safety Information.